Nanobiotix develops nanoparticle medicines, led by a candidate designed to boost the effect of radiotherapy on cancer tumors. NBTX last reported earnings on Tue, Sep 29, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 15 | Guggenheim | Assumed coverage | Buy | |
| Jun 4 | Leerink Partners | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in NBTX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBTX is in one of them and how their past NBTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NBTX in an article yet. Here's the latest on the wider market.
About Nanobiotix S.A.
Nanobiotix is a biotechnology company based in Paris, France, that develops medicines built on nanoparticles. Its lead candidate, JNJ-1900 (NBTXR3), is designed to increase the effect of radiotherapy on tumors while limiting the dose to surrounding healthy tissue, and it is in clinical trials for several cancer types, mainly head and neck and lung cancer. The company also works on earlier stage platforms meant to help other drugs reach target tissues and to treat neurological conditions. Its main partner for the lead candidate is Johnson & Johnson, and the medicines are aimed at people receiving cancer treatment.
- Headquarters
- Paris, France